Forthyron 400

Main information

  • Trade name:
  • Forthyron 400
  • Pharmaceutical form:
  • Tablet
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Forthyron 400
    Germany
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • levothyroxine sodium
  • Therapeutic area:
  • Dogs

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0217/002
  • Authorization date:
  • 14-07-2010
  • EU code:
  • UK/V/0217/002
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Revised:October2010

AN:01015/2009

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

Forthyron400microgramtablet

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

ActiveSubstance:

400µglevothyroxinesodiumpertabletequivalentto388µglevothyroxine

Forafulllistofexcipients,seesection6.1

3. PHARMACEUTICALFORM

Tablet

Whitetooffwhiteroundtablets,scoredononeside

Tabletsdivisibleinto4parts

4. CLINICALPARTICULARS

4.1. Targetspecies

Dogs.

4.2. Indicationsforuse,specifyingthetargetspecies

Forthetreatmentofhypothyroidismindogs.

4.3. Contra-indications

Donotuseindogssufferingfromuncorrectedadrenalinsufficiency.

4.4. Specialwarningsforeachtargetspecies

Thediagnosishypothyroidismshouldbeconfirmedwithappropriatetests.

4.5. Specialprecautionsforuse

Specialprecautionsforuseinanimals

Asuddenincreaseindemandforoxygendeliverytoperipheraltissues,plusthechronotropic

effectsoflevothyroxinesodium,mayplaceunduestressonapoorlyfunctioningheart,causing

decompensationandsignsofcongestiveheartfailure.Hypothyroiddogssufferingfrom

hypoadrenocorticismhaveadecreasedabilitytometaboliselevothyroxinesodiumand

thereforeanincreasedriskofthyrotoxicosis.Dogswithconcurrenthypoadrenocorticismand

hypothyroidismshouldbestabilisedwithglucocorticoidandmineralocorticoidtreatmentprior

totreatmentwithlevothyroxinesodiumtoavoidprecipitatingahypoadrenocorticalcrisis.

Afterthis,thyroidtestsshouldberepeated,thengradualintroductionoflevothyroxinetherapy,

startingwith25%ofthenormaldose,increasingby25%incrementseveryfortnightuntil

optimalstabilisationisachievedisrecommended.Gradualintroductionoftherapyisalso

recommendedfordogswithotherconcurrentillnesses;particularlydiabetesmellitusandrenal

orhepaticdysfunction.

Specialprecautionstobetakenbythepersonadministeringthemedicinalproduct

toanimals

Washhandsafteradministeringthetablets.Pregnantwomenshouldhandletheproductwith

caution.

Revised:October2010

AN:01015/2009

4.6. Adversereactions(frequencyandseriousness)

Restorationofphysicalactivitymayunmaskorintensifyotherproblems,suchas

osteoarthrosis.Adverseeffectsofthyroidhormonesaregenerallyassociatedwithexcessive

dosageandcorrespondtothesymptomsofhyperthyroidism.Seealsosection4.10.

4.7. Useduringpregnancy,lactationorlay

Thesafetyofuseoftheproductduringpregnancyhasnotbeenestablishedthroughspecial

reproductionstudies.However,levothyroxineisanendogenoussubstanceandthyroid

hormonesareessentialforthedevelopingfoetus,especiallyduringthefirstperiodof

gestation.Hypothyroidismduringpregnancymayresultinmajorcomplicationssuchasfoetal

deathandapoorperinataloutcome.Maintenancedoseoflevothyroxinesodiummayneed

adjustmentduringpregnancy.Pregnantbitchesshouldthereforebemonitoredonaregular

basefromconceptionuntilseveralweeksafterdelivery.

4.8.Interactionswithothermedicinalproductsandotherformsofinteraction

Avarietyofdrugsmayimpairplasmaortissuebindingofthethyroidhormonesoralterthyroid

hormonemetabolism(eg.barbiturates,antacids,anabolicsteroids,diazepam,furosemide,

mitotane,phenylbutazone,phenytoin,propranolol,largedosesofsalicylates,and

sulphonamides.).Whentreatingdogsthatarereceivingconcurrentmedicationtheproperties

ofthesedrugsshouldbetakenintoconsideration.

Anincreaseinthedosageofdigitalismaybenecessaryinapatientthathadpreviously

compensatedcongestiveheartfailureandthatisplacedonthyroidhormonesupplementation.

Estrogensmayincreasethyroidrequirements.

Ketaminemaycausetachycardiaandhypertensionwhenusedinpatientsreceivingthyroid

hormones.Theeffectofcatecholaminesandsympatiomimeticsisincreasedbylevothyroxine.

Followingtreatmentofhypothyroidismindogswithconcurrentdiabetes,carefulmonitoringof

diabeticcontrolisrecommended.

Mostdogsonchronichigh-dose,dailyglucocorticoidtherapywillhaveverylowor

undetectableserumT

concentrations,aswellassubnormalT

values.

4.9 Amountstobeadministeredandadministrationroute

Therecommendedstartingdosageoflevothyroxinesodiumis10µg/kgbodyweightorally

every12hour.Becauseofvariabilityinabsorptionandmetabolism,thedosagemayrequire

alterationsbeforeacompleteclinicalresponseisobserved.Theinitialdosageandfrequency

ofadministrationaremerelyastartingpoint.Therapyhastobehighlyindividualisedand

tailoredtotherequirementsoftheindividualdog.Wheninitiatingdosingofdogsweighing

lessthan5kgbodyweight,aquarterofone200μgtabletshouldbeadministeredoncedaily.

Suchcasesshouldbemonitoredcarefully.Inthedog,absorptionoflevothyroxinesodiummay

beaffectedbythepresenceoffood.Thetimingoftreatmentanditsrelationtofeedingshould

thereforebekeptconsistentfromdaytoday.Toadequatelymonitortherapy,troughvalues

(justpriortotreatment)andpeakvalues(aboutthreehoursafterdosing)ofplasmaT

canbe

measured.InadequatelydoseddogspeakplasmaconcentrationofT

shouldbeinthehigh-

normalrange(approximately30to47nmol/l)andtroughvaluesshouldbeabove

approximately19nmol/l.IfT

levelsareoutsidethisrangethelevothyroxinedosecanbe

adjustedin50to200µgincrementsuntilthepatientisclinicallyeuthyroidandserumT

is

Revised:October2010

AN:01015/2009

withinthereferencerange.PlasmaT

levelscanberetestedtwoweeksafterchangeof

dosage,butclinicalimprovementisanequallyimportantfactorindeterminingindividual

dosageandthiswilltakefourtoeightweeks.Whentheoptimumreplacementdosehasbeen

attained,clinicalandbiochemicalmonitoringmaybeperformedevery

6 –12months.

Tobreakatabletaccuratelyandeasily,placethetabletscoresideup

andapplypressurewithyourthumb.

Tobreakthetabletintwoparts;holdonehalfofthetabletdownandpressdowntheotherhalf.

4.10.Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Followingadministrationofoverdosesthyrotoxicosiscouldoccur.Thyrotoxicosisasaside

effectofmildoversupplementationisuncommonindogs,owingtothecanineabilityto

catabolizeandexcretethyroidhormones.Incaseofaccidentalintakeoflargeamountsof

Forthyrontabletsabsorptioncanbedecreasedbyinductionofvomitingandoral

administrationofbothactivatedcharcoalandmagnesiumsulphateonce.

Overdosesofthreeuptosixtimeslabelrecommendedstartingdosefor4consecutiveweeks

inhealthy,euthyroiddogsresultedinnosignificantclinicalsignsthatcouldbeattributedto

treatment.Singleoverdoseupto3-6xtherecommendeddosedoesnotposeathreattothe

dog,andnoactionsarenecessary.However,followingchronicover-supplementation,clinical

signsofhyperthyroidismsuchaspolydipsia,polyuria,panting,weightlosswithoutanorexia,

andeitherorbothtachycardiaandnervousnessmaytheoreticallyoccur.Thepresenceof

thesesignsshouldresultinevaluationofT

serumconcentrationstoconfirmthediagnosis,

andimmediatediscontinuanceofthesupplementation.Oncethesignshaveabated(daysto

weeks),thethyroiddosagehasbeenreviewed,andtheanimalhasfullyrecovered,alower

dosagemaybeinstituted,withtheanimalbeingmonitoredclosely.

4.11.Withdrawalperiods

Notapplicable.

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:syntheticthyroidhormones

ATCvetcode:QH03AA01.

Revised:October2010

AN:01015/2009

5.1. Pharmacodynamicproperties

Pharmacologicallylevothyroxineisclassifiedasahormonalpreparationthatreplaces

deficientendogenoushormones.

LevothyroxineT

isconvertedtotriiodothyronineT

actsoncellularprocessesviaspecific

ligand-receptorinteractionswiththenucleus,themitochondria,andtheplasmamembrane.

InteractionofT

withbindingsitesleadstoaugmentedtranscriptionofDNAormodulationof

RNA,thusinfluencingproteinsynthesisandenzymeaction.

Thyroidhormonesactonmanydifferentcellularprocesses.Indevelopinganimalsandhuman

beings,theyarecrucialdeterminantsofnormaldevelopment,especiallyinthecentralnervous

system.Thyroidsupplementationincreasesbasalcellularmetabolismandoxygen

consumptiontherebyaffectingthefunctionofvirtuallyallorgansystems.

5.2. Pharmacokineticparticulars

SomedogsappearedtoconsistentlyeitherabsorbL-thyroxinebetterand/oreliminateitmore

slowlythandootherdogs.Furthermoreabsorptionandeliminationrateisinfluencedbydaily

intakeoflevothyroxinesodium(highabsorption/loweliminationincaseoflowintakeandvice

versaincaseofhighintake).Thevariabilityinpharmacokineticparametersbetween

individualdogsisconsiderableand,althoughthepresenceoffoodmayaffectabsorption,itis

consideredtohaveaminoreffectontheparametersoverall.Absorptionisrelativelyslowand

incomplete:InmostcasesT

occursbetween1to5hoursafteroraladministration,mean

variesmorethan3foldbetweendogsonthesamedoses.Inadequatelydoseddogs

theplasmapeakapproachesorslightlyexceedstheupperlimitofnormalplasmaT

levels,

andbytheendof12hoursafteroraladministration,plasmaT

usuallydeclinestothelower

halfofthenormalrange.TheratesofdisappearanceofT

fromtheplasmaareslowedin

hypothyroidism.Alargepartofthethyroxineistakenupbytheliver.L-thyroxineisboundto

plasma-proteinsandplasmalipoproteins.Partofadoseofthyroxineismetabolisedtothe

morepotenttriiodothyronine(T

)bydeiodination.Theprocessofdeiodinationcontinues.

Thesefurtherdeiodinatedmetabolicproducts(otherthanT

andT

)donothavethyromimetic

activity.Otherpathwaysofthyroidhormonemetabolismincludeconjugationtoformsoluble

glucuronidesandsulphatesforbiliaryorurinaryexcretionaswellascleavageoftheether

linkageoftheiodothyroninemolecule.Inthedog,over50%oftheT

producedeachdayare

lostinthefaeces.TheextrathyroidalbodystoresofT

areeliminatedandreplacedinabout1

day.

6. PHARMACEUTICALPARTICULARS

6.1. Listofexcipients

Calciumhydrogenphosphatedihydrate,

Cellulose,Microrcrystalline,

SodiumStarchGlycolate(typeA),

Magnesiumstearate.

6.2. Incompatibilities

Notapplicable

Revised:October2010

AN:01015/2009

6.3. Shelf-life

Shelf-lifeoftheveterinarymedicinalproductaspackagedforsale:2years

Tabletportionscanbekeptfor4daysintheblisterpack.

6.4. Specialprecautionsforstorage

Donotstoreabove25°C.

6.5. Natureandcontentsofimmediatepackaging

Blisters,consistingofaluminiumfoilandawhite,opaquePVC/PE/PVDCfoil.

10Tabletsperblister,5,25,or50blisterspercarton,50,250or500tabletspercarton.

Notallpacksizesmaybemarketed.

6.6. Specialprecautionsforthedisposalofunusedveterinarymedicinalproductor

wastematerials,derivedfromtheuseofsuchproductsifappropriate.

Anyunusedproductorwastematerialshouldbedisposedofinaccordancewithnational

requirements.

7. MARKETINGAUTHORISATIONHOLDER

EurovetAnimalHealthB.V.,Handelsweg25,5531AEBladel,TheNetherlands

8. MARKETINGAUTHORIZATIONNUMBER

Vm16849/4006

9. DATEOFRENEWALOFTHEAUTHORISATION

13April2010

10. DATEOFREVISIONOFTHETEXT

October2010

1-12-2018

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Trichoderma reesei (strain DP‐Nzd22)

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Trichoderma reesei (strain DP‐Nzd22)

Published on: Fri, 30 Nov 2018 The food enzyme endo‐1,4‐β‐xylanase (EC 3.2.1.8) is produced with a genetically modified Trichoderma reesei (strain DP‐Nzd22) by DuPont. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. The endo‐1,4‐β‐xylanase is intended to be used in distilled alcohol production, bakery and brewery. Residual amounts of total organic solids (TOS) are removed during the production of dis...

Europe - EFSA - European Food Safety Authority Publications

1-11-2018

Safety evaluation of the food enzyme α‐amylase from a genetically modified Aspergillus niger (strain NZYM‐MC)

Safety evaluation of the food enzyme α‐amylase from a genetically modified Aspergillus niger (strain NZYM‐MC)

Published on: Wed, 31 Oct 2018 00:00:00 +0100 The food enzyme alpha‐amylase (4‐α‐d‐glucan glucanohydrolase; EC 3.2.1.1) is produced with the genetically modified strain of Aspergillus niger by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. This α‐amylase is intended to be used in starch processing for glucose syrups production, beverage alcohol (distilling) processes and baking proces...

Europe - EFSA - European Food Safety Authority Publications

20-10-2018

Scientific Opinion on Flavouring Group Evaluation 200, Revision 1 (FGE.200 Rev.1): 74 α,β‐unsaturated aliphatic aldehydes and precursors from chemical subgroup 1.1.1 of FGE.19

Scientific Opinion on Flavouring Group Evaluation 200, Revision 1 (FGE.200 Rev.1): 74 α,β‐unsaturated aliphatic aldehydes and precursors from chemical subgroup 1.1.1 of FGE.19

Published on: Fri, 19 Oct 2018 00:00:00 +0200 The Panel on Food Additives and Flavourings of the European Food Safety Authority was requested to evaluate the genotoxic potential of 74 flavouring substances from subgroup 1.1.1 of FGE.19 in the Flavouring Group Evaluation 200 Revision 1 (FGE.200 Rev1). In FGE.200, genotoxicity studies were provided for one representative substance, namely hex‐2(trans)‐enal [FL‐no: 05.073], and for other two substances in the same subgroup, namely 2‐dodecenal [FL‐no: 05.03...

Europe - EFSA - European Food Safety Authority Publications

11-10-2018

Re‐evaluation of oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (E 479b) as a food additive

Re‐evaluation of oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (E 479b) as a food additive

Published on: Wed, 10 Oct 2018 00:00:00 +0200 The EFSA Panel on Food Additives and Flavourings (FAF) provides a scientific opinion re‐evaluating the safety of thermally oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (TOSOM) (E 479b) when used as a food additive. The Scientific Committee on Food (SCF) and the Joint FAO/WHO Expert Committee on Food Additives (JECFA) derived an acceptable daily intake (ADI) of 25 and 30 mg/kg body weight (bw) per day, respectively. There was n...

Europe - EFSA - European Food Safety Authority Publications

31-8-2018

Public Notification: PremierZen Gold 4000 contains hidden drug ingredient

Public Notification: PremierZen Gold 4000 contains hidden drug ingredient

The Food and Drug Administration is advising consumers not to purchase or use PremierZen Gold 4000, a product promoted for sexual enhancement. This product was identified during an examination of international mail shipments.

FDA - U.S. Food and Drug Administration

3-8-2018

Scientific guideline:  Ledipasvir/sofosbuvir film-coated tablet 90 mg/400 mg product-specific bioequivalence guidance, adopted

Scientific guideline: Ledipasvir/sofosbuvir film-coated tablet 90 mg/400 mg product-specific bioequivalence guidance, adopted

Ledipasvir/sofosbuvir film-coated tablet 90 mg/400 mg product-specific bioequivalence guidance

Europe - EFSA - European Food Safety Authority EFSA Journal

14-6-2018

Blokhuis: maak postnatale depressie bespreekbaar

Blokhuis: maak postnatale depressie bespreekbaar

In Nederland ontwikkelen jaarlijks ruim 23.400 vrouwen een depressie na de bevalling. Dat is 1 op de 8 moeders. Velen van hen durven hun situatie niet aan te kaarten. Zij zijn bang om gezien te worden als een slechte moeder (47,4%) en willen anderen niet belasten (52,2%), blijkt uit een peiling onder vrouwen die (signalen van) een postnatale depressie hebben gehad. Hierdoor blijft postnatale depressie, ook wel postpartum depressie (PPD) genoemd, te vaak onbesproken. Daarom geeft staatssecretaris Paul Blo...

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

19-6-2015

Global operation against illicit medicines completed

Global operation against illicit medicines completed

A global medicine operation results in 156 arrests and shutdown of more than 2,400 websites.

Danish Medicines Agency

25-7-2018

#FDA issues updated safety communication for Zoll LifeVest 4000 regarding “Message Code 102,” and updated patient checklist.  https://go.usa.gov/xUEPn  #MedicalDevices

#FDA issues updated safety communication for Zoll LifeVest 4000 regarding “Message Code 102,” and updated patient checklist. https://go.usa.gov/xUEPn  #MedicalDevices

#FDA issues updated safety communication for Zoll LifeVest 4000 regarding “Message Code 102,” and updated patient checklist. https://go.usa.gov/xUEPn  #MedicalDevices

FDA - U.S. Food and Drug Administration

29-5-2018

EU/3/14/1400 (Orphan Europe S.A.R.L.)

EU/3/14/1400 (Orphan Europe S.A.R.L.)

EU/3/14/1400 (Active substance: (1S,4R,5R,7S)-3,4-dibenzyl-2-oxo-6,8-dioxa-3-azabyciclo[3.2.1]octane-7-carboxylic acid-L-lysine) - Transfer of orphan designation - Commission Decision (2018)3402 of Tue, 29 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/185/14/T/01

Europe -DG Health and Food Safety